Sanofi (SNY) and Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has ...

(Reuters) - Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201. The French healthcare group will ...

March 20 (Reuters) - Sanofi (SASY.PA), opens new tab on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing over $600 million upfront for Dren Bio’s clinical-stage bispecific antibody, with more than $1 billion in ...

Paris, March 20, 2025. Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201 ...

Dren Bio deep B-cell depleter program has the potential to ... The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site ...

Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201. The French healthcare group will acquire the Dren Bio ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front Paris, ...

After the acquisition of Dren-0201, Dren Bio will continue to operate independently to advance its pipeline of antibody therapeutics that selectively deplete pathogenic cells and other disease ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front ...